Randomized Trial: Efficacy and Safety of Lumateperone for Treatment of Schizophrenia

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial – JAMA Psychiatry (free)

Editorial: The Potential Role of Lumateperone—Something Borrowed? Something New? – JAMA Psychiatry (free for a limited period)

Related Commentary on Twitter

In a Phase 3 trial, lumateperone (42mg) demonstrated significant efficacy for improving the symptoms of schizophrenia with a favorable safety profile. https://t.co/0eukuf1Qrf

— JAMA Psychiatry (@JAMAPsych) January 8, 2020